Increasing the α 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer

키워드

참고문헌 (165)

1. Moremen KW, "Vertebrate protein glycosylation: diversity, synthesis and function", Nat Rev Mol Cell Biol, 13, pp.448~462 (2012)
2. Zoldo?V, "Genomics and epigenomics of the human glycome", Glycoconj J, 30, pp.41~50 (2013)
3. Schachter H, "Glycosylation diseases: quo vadis", Biochim Biophys Acta, 1792, pp.925~930 (2009)
4. Stanley P, "Essentials of glycobiology. 2nd ed", pp.101~114 (2009), Cold Spring Harbor Laboratory Press
5. Brockhausen I, "Essentials of glycobiology. 2nd ed", pp.115~128 (2009), Cold Spring Harbor Laboratory Press
6. Miyagi T, "Sialidase significance for cancer progression", Glycoconj J, 29, pp.567~577 (2012)
7. Dall뭀lio F, "Mechanisms of cancer-associated glycosylation changes", Front Biosci (Landmark Ed), 17, pp.670~699 (2012)
8. Schultz MJ, "Regulation of the metastatic cell phenotype by sialylated glycans", Cancer Metastasis Rev, 31, pp.501~518 (2012)
9. Adamczyk B, "Glycans as cancer biomarkers", Biochim Biophys Acta, 1820, pp.1347~1353 (2012)
10. Varki A, "Sialic acids in human health and disease", Trends Mol Med, 14, pp.351~360 (2008)
11. Yamaguchi K, "Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase", PLoS One, 7, pp.e41132~ (2012)
12. Varki NM, "Diversity in cell surface sialic acid presentations: implications for biology and disease", Lab Invest, 87, pp.851~857 (2007)
13. Varki A, "Colloquium paper : uniquely human evolution of sialic acid genetics and biology", Proc Natl Acad Sci U S A, 107(Suppl 2), pp.8939~8946 (2010)
14. Li Y, "Sialic acid metabolism and sialyltransferases: natural functions and applications", Appl Microbiol Biotechnol, 94, pp.887~905 (2012)
15. Audry M, "Current trends in the structure-activity relationships of sialylt ransferases", Glycobiology, 21, pp.716~726 (2011)
16. Chen X, "Advances in the biology and chemistry of sialic acids", ACS Chem Biol, 5, pp.163~176 (2010)
17. Tsuji S, "Molecular cloning and functional analysis of sialyltransferases", J Biochem, 120, pp.1~13 (1996)
18. Harduin-Lepers A, "1994, the year of sialyltransferases", Glycobiology, 5, pp.741~758 (1995)
19. Datta AK, "Comparative sequence analysis in the sialyltransferase protein family: analysis of motifs", Curr Drug Targets, 10, pp.483~498 (2009)
20. Harduin-Lepers A, "The human sialyltransferase family", Biochimie, 83, pp.727~737 (2001)
21. Lee HJ, "Identification of possible candidate biomarkers for local or whole body radiation exposure in C57BL", 6 mice, 2007, pp.69, 1272~1281
22. Hennet T, "Immune regulation by the ST6Gal sialyltransferase", Proc Natl Acad Sci U S A, 95, pp.4504~4509 (1998)
23. Stamenkovic I, "CD22 binds to alpha-2,6-sialyltransferase-dependent epitopes on COS cells", Cell, 68, pp.1003~1004 (1992)
24. Stamenkovic I, "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells", Cell, 66, pp.1133~1144 (1991)
25. Collins BE, "Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling", Nat Immunol, 7, pp.199~206 (2006)
26. Hedlund M, "alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo", Cancer Res, 68, pp.388~394 (2008)
27. Swindall AF, "ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines", Cancer Res, 73, pp.2368~2378 (2013)
28. Shaikh FM, "Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms", Exp Cell Res, 314, pp.2941~2950 (2008)
29. Dall뭀lio F, "Beta-galactoside alpha2,6-sialyltransferase and the sialyl alpha2,6-galactosyl-linkage in tissues and cell lines", Methods Mol Biol, 347, pp.157~170 (2006)
30. Chiricolo M, "Phenotypic changes induced by expression of beta-galactoside alpha2,6 sialyltransferase I in the human colon cancer cell line SW948", Glycobiology, 16, pp.146~154 (2006)
31. Seales EC, "Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility", Cancer Res, 65, pp.4645~4652 (2005)
32. Birkenkamp-Demtroder K, "Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid", Gut, 54, pp.374~384 (2005)
33. Zhu Y, "Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro", Biochim Biophys Acta, 1536, pp.148~160 (2001)
34. Nemoto-Sasaki Y, "Correlation between the sialylation of cell surface Thomsen-Friedenreich antigen and the metastatic potential of colon carcinoma cells in a mouse model", Glycoconj J, 18, pp.895~906 (2001)
35. Lise M, "Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients", Hybridoma, 19, pp.281~286 (2000)
36. Dall’Olio F, "Beta-galactoside alpha2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with Sambucus nigra agglutinin", Int J Cancer, 88, pp.58~65 (2000)
37. Dall’Olio F, "The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role", Glycoconj J, 17, pp.669~676 (2000)
38. Murayama T, "Colon carcinoma glycoproteins carrying alpha 2,6-linked sialic acid reactive with Sambucus nigra agglutinin are not constitutively expressed in normal human colon mucosa and are distinct from sialyl-Tn antigen", Int J Cancer, 70, pp.575~581 (1997)
39. Swindall AF, "Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells", J Biol Chem, 286, pp.22982~22990 (2011)
40. Sawada M, "Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression", Int J Cancer, 97, pp.180~185 (2002)
41. Dall’Olio F, "Sialyltransferases in cancer", Glycoconj J, 18, pp.841~850 (2001)
42. Bresalier RS, "Cell surface sialoprotein alterations in metastatic murine colon cancer cell lines selected in an animal model for colon cancer metastasis", Cancer Res, 50, pp.1299~1307 (1990)
43. Yue T, "Microarrays in glycoproteomics research", Clin Lab Med, 29, pp.15~29 (2009)
44. Medzihradszky KF, "Characterization of protein N-glycosylation", Methods Enzymol, 405, pp.116~138 (2005)
45. Varki A, "Symbol nomenclature for glycan representation", Proteomics, 9, pp.5398~5399 (2009)
46. Varki A, "Essentials of glycobiology. 2nd ed" (2009), Cold Spring Harbor Laboratory Press
47. Varki A, "Diversity in the sialic acids", Glycobiology, 2, pp.25~40 (1992)
48. Yin J, "Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells", Cancer Res, 66, pp.2937~2945 (2006)
49. Schauer R, "Sialic acids as regulators of molecular and cellular interactions", Curr Opin Struct Biol, 19, pp.507~514 (2009)
50. Schauer R, "Achievements and challenges of sialic acid research", Glycoconj J, 17, pp.485~499 (2000)
51. Jass JR, "Altered mucin expression in the gastrointestinal tract: a review", J Cell Mol Med, 5, pp.327~351 (2001)
52. Jass JR, "Mucin core proteins as differentiation markers in the gastrointestinal tract", Histopathology, 37, pp.561~564 (2000)
53. Byrd JC, "Mucins and mucin binding proteins in colorectal cancer", Cancer Metastasis Rev, 23, pp.77~99 (2004)
54. Saez C, "Mucinous (colloid) adenocarcinomas secrete distinct O-acylated forms of sialomucins: a histochemical study of gastric, colorectal and breast adenocarcinomas", Histopathology, 39, pp.554~560 (2001)
55. Yamaoka Y, "Increasing evidence of the role of Helicobacter pylori SabA in the pathogenesis of gastroduodenal disease", J Infect Dev Ctries, 2, pp.174~181 (2008)
56. Lewis AL, "Host sialoglycans and bacterial sialidases: a mucosal perspective", Cell Microbiol, 14, pp.1174~1182 (2012)
57. Aspholm M, "SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans", PLoS Pathog, 2, pp.e110~ (2006)
58. Shen Y, "O-acetylation and de-O-acetylation of sialic acids in human colorectal carcinoma", Eur J Biochem, 271, pp.281~290 (2004)
59. Shen Y, "Regulation of sialic acid O-acetylation in human colon mucosa", Biol Chem, 385, pp.145~152 (2004)
60. Corfield AP, "Mucin degradation in the human colon: production of sialidase, sialate O-acetylesterase, N-acetylneuraminate lyase, arylesterase, and glycosulfatase activities by strains of fecal bacteria", Infect Immun, 60, pp.3971~3978 (1992)
61. Corfield AP, "Reduction of sialic acid O-acetylation in human colonic mucins in the adenoma-carcinoma sequence", Glycoconj J, 16, pp.307~317 (1999)
62. Kitazume S, "Involvement of proteases in glycosyltransferase secretion: Alzheimer’s beta-secretase-dependent cleavage and a following processing by an aminopeptidase", Glycoconj J, 21, pp.25~29 (2004)
63. Kitazume S, "Alzheimer’s beta-secretase cleaves a glycosyltransferase as a physiological substrate", Glycoconj J, 20, pp.59~62 (2004)
64. Alhadeff JA, "Purification of human liver glycoprotein sialyltransferase by affinity chromatography", J Biochem Biophys Methods, 6, pp.229~233 (1982)
65. Ratnam S, "Characterization of serum, liver, and intestinal sialyltransferases from rats treated with colchicine", Biochem Cell Biol, 65, pp.183~187 (1987)
66. Kessel D, "Elevated plasma sialyltransferase in the cancer patient", Cancer Res, 35, pp.670~672 (1975)
67. Nakamura R, "The presence of cytidine 5’-monophosphosialic acid: glycoprotein sialyltransferase in human saliva", J Dent Res, 54, pp.188~ (1975)
68. Angata K, "Polysialyltransferases: major players in polysialic acid synthesis on the neural cell adhesion molecule", Biochimie, 85, pp.195~206 (2003)
69. Spiro MJ, "Glycoprotein biosynthesis: studies on thyroglobulin. Thyroid sialyltransferase", J Biol Chem, 243, pp.6520~6528 (1968)
70. Maksimovic J, "Conservation of the ST6Gal I gene and its expression in the mammary gland", Glycobiology, 21, pp.467~481 (2011)
71. Dalziel M, "Mouse ST6Gal sialyltransferase gene expression during mammary gland lactation", Glycobiology, 11, pp.407~412 (2001)
72. Paulson JC, "Purification of a sialyltransferase from bovine colostrum by affinity chromatography on CDP-agarose", J Biol Chem, 252, pp.2356~2362 (1977)
73. Griffiths J, "Plasma sialyl transferase total and isoenzyme activity in the diagnosis of cancer of the colon", Clin Biochem, 15, pp.46~48 (1982)
74. Gessner P, "Enhanced activity of CMP-neuAc:Gal beta 1-4GlcNAc:alpha 2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients", Cancer Lett, 75, pp.143~149 (1993)
75. Lee M, "Cleavage of ST6Gal I by radiation-induced BACE1 inhibits golgi-anchored ST6Gal I-mediated sialylation of integrin β1 and migration in colon cancer cells", Radiat Oncol, 7, pp.47~ (2012)
76. Weiser MM, "Serum levels of glycosyltransferases and related glycoproteins as indicators of cancer: biological and clinical implications", Crit Rev Clin Lab Sci, 14, pp.189~239 (1981)
77. Strous GJ, "Golgi and secreted galactosyltransferase", CRC Crit Rev Biochem, 21, pp.119~151 (1986)
78. Cho SK, "A soluble form of alpha1,3-galactosyltransferase functions within cells to galactosylate glycoproteins", J Biol Chem, 272, pp.13622~13628 (1997)
79. Zhu G, "Two soluble glycosyltransferases glycosylate less efficiently in vivo than their membrane bound counterparts", Glycobiology, 8, pp.831~840 (1998)
80. Miyagi T, "Mammalian sialidases: physiological and pathological roles in cellular functions", Glycobiology, 22, pp.880~896 (2012)
81. Yamanami H, "Down-regulation of sialidase NEU4 may contribute to invasive properties of human colon cancers", Cancer Sci, 98, pp.299~307 (2007)
82. Uemura T, "Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4", Oncogene, 28, pp.1218~1229 (2009)
83. Shiozaki K, "Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4", J Biol Chem, 286, pp.21052~21061 (2011)
84. Shiozaki K, "Plasma membrane-associated sialidase (NEU3) promotes formation of colonic aberrant crypt foci in azoxymethane-treated transgenic mice", Cancer Sci, 100, pp.588~594 (2009)
85. Kakugawa Y, "Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression", Proc Natl Acad Sci U S A, 99, pp.10718~10723 (2002)
86. Jass JR, "Heredity and DNA methylation in colorectal cancer", Gut, 56, pp.154~155 (2007)
87. Jass JR, "Colorectal cancer: a multipathway disease", Crit Rev Oncog, 12, pp.273~287 (2006)
88. Hammoud SS, "Epigenetic regulation of colon cancer and intestinal stem cells", Curr Opin Cell Biol, 25, pp.177~183 (2013)
89. Grady WM, "Genomic and epigenetic instability in colorectal cancer pathogenesis", Gastroenterology, 135, pp.1079~1099 (2008)
90. Fearon ER, "A genetic model for colorectal tumorigenesis", Cell, 61, pp.759~767 (1990)
91. Cancer Genome Atlas Network, "Comprehensive molecular characterization of human colon and rectal cancer", Nature, 487(7407), pp.330~337 (2012), Nature Publishing Group
92. Takami K, "Multistep carcinogenesis in colorectal cancers", Southeast Asian J Trop Med Public Health, (26 Suppl 1), pp.190~196 (1995)
93. Kwong LN, "APC and its modifiers in colon cancer", Adv Exp Med Biol, 656, pp.85~106 (2009)
94. Zeichner SB, "A De Novo Germline APC Mutation (3927del5) in a Patient with Familial Adenomatous Polyposis: Case Report and Literature Review", Clin Med Insights Oncol, 6, pp.315~323 (2012)
95. Kanthan R, "Molecular events in primary and metastatic colorectal carcinoma: a review", Patholog Res Int, 2012, pp.597497~ (2012)
96. Valastyan S, "Tumor metastasis: molecular insights and evolving paradigms", Cell, 147, pp.275~292 (2011)
97. Gretschel S, "Clinical relevance of sialyltransferases ST6GAL-I and ST3GAL-III in gastric cancer", Oncology, 65, pp.139~145 (2003)
98. Schultz MJ, "ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells", J Ovarian Res, 6, pp.25~ (2013)
99. Lin S, "Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells", Exp Cell Res, 276, pp.101~110 (2002)
100. Peyrat JP, "Regulation of sialyltransferase expression by estradiol and 4-OH-tamoxifen in the human breast cancer cell MCF-7", Mol Cell Biol Res Commun, 3, pp.48~52 (2000)
101. Mondal S, "Elevated mRNA level of hST6Gal I and hST3Gal V positively correlates with the high risk of pediatric acute leukemia", Leuk Res, 34, pp.463~470 (2010)
102. Wang PH, "Enhanced expression of alpha 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma", Gynecol Oncol, 89, pp.395~401 (2003)
103. Lee M, "Adhesion of ST6Gal I-mediated human colon cancer cells to fibronectin contributes to cell survival by integrin beta1-mediated paxillin and AKT activation", Oncol Rep, 23, pp.757~761 (2010)
104. Lee M, "Sialylation of integrin beta1 is involved in radiation-induced adhesion and migration in human colon cancer cells", Int J Radiat Oncol Biol Phys, 76, pp.1528~1536 (2010)
105. Harvey BE, "Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases", Cancer Res, 52, pp.1775~1779 (1992)
106. Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
107. O’Neil BH, "Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials", Oncologist, 13, pp.1074~1083 (2008)
108. Hehlgans S, "Signalling via integrins: implications for cell survival and anticancer strategies", Biochim Biophys Acta, 1775, pp.163~180 (2007)
109. Bellis SL, "Variant glycosylation: an underappreciated regulatory mechanism for beta1 integrins", Biochim Biophys Acta, 1663, pp.52~60 (2004)
110. Agnantis NJ, "Tumor markers in cancer patients: an update of their prognostic significance: Part II", In vivo, 18, pp.481~488 (2004)
111. Seales EC, "Ras oncogene directs expression of a differentially sialylated, functionally altered beta1 integrin", Oncogene, 22, pp.7137~7145 (2003)
112. Dalziel M, "Ras oncogene induces beta-galactoside alpha2,6-sialyltransferase (ST6Gal I) via a RalGEF-mediated signal to its housekeeping promoter", Eur J Biochem, 271, pp.3623~3634 (2004)
113. Zhuo Y, "Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis", J Biol Chem, 283, pp.22177~22185 (2008)
114. Zhuo Y, "Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function", J Biol Chem, 286, pp.5935~5941 (2011)
115. Margadant C, "Mechanisms of integrin activation and trafficking", Curr Opin Cell Biol, 23, pp.607~614 (2011)
116. Nam JM, "beta1 integrin targeting to enhance radiation therapy", Int J Radiat Biol, 85, pp.923~928 (2009)
117. Cordes N, "beta1 integrin as a molecular therapeutic target", Int J Radiat Biol, 83, pp.753~760 (2007)
118. Mladenov E, "DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy", Front Oncol, 3, pp.113~ (2013)
119. Vaupel P, "Tumor microenvironmental physiology and its implications for radiation oncology", Semin Radiat Oncol, 14, pp.198~206 (2004)
120. Sandfort V, "Cell adhesion-mediated radioresistance revisited", Int J Radiat Biol, 83, pp.727~732 (2007)
121. Cordes N, "Cell adhesion-mediated radioresistance (CAM-RR). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro", Strahlenther Onkol, 179, pp.337~344 (2003)
122. Cordes N, "Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity", Cancer Res, 64, pp.5683~5692 (2004)
123. Eke I, "Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis", Cancer Res, 73, pp.5869~5879 (2013)
124. Lee M, "Protein sialylation by sialyltransferase involves radiation resistance", MOLECULAR CANCER RESEARCH, 6, pp.1316~1325 (2008), AMER ASSOC CANCER RESEARCH
125. Marin JJ, "Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer", Drug Metab Rev, 44, pp.148~172 (2012)
126. Benson AB 3rd, "American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer", J Clin Oncol, 22, pp.3408~3419 (2004)
127. Sobrero A, "Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal", Lancet Oncol, 7, pp.515~516 (2006)
128. Cartwright TH, "Treatment decisions after diagnosis of metastatic colorectal cancer", Clin Colorectal Cancer, 11, pp.155~166 (2012)
129. Maughan TS, "Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial", Lancet, 377, pp.2103~2114 (2011)
130. Hewish M, "First-line treatment of advanced colorectal cancer", Lancet, 377, pp.2060~2062 (2011)
131. Normanno N, "Implications for KRAS status and EGFR-targeted therapies in metastatic CRC", Nat Rev Clin Oncol, 6, pp.519~527 (2009)
132. Walther A, "Genetic prognostic and predictive markers in colorectal cancer", Nat Rev Cancer, 9, pp.489~499 (2009)
133. De Roock W, "KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer", Lancet Oncol, 12, pp.594~603 (2011)
134. Sartore-Bianchi A, "Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer", Cancer Treat Rev, (36 Suppl 3), pp.S1~S5 (2010)
135. Wheeler DL, "Understanding resistance to EGFR inhibitors-impact on future treatment strategies", Nat Rev Clin Oncol, 7, pp.493~507 (2010)
136. Moran AE, "Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL", 6J- Min, J Biol Chem, pp.2004, 279[DOI]
137. Roberts RB, "Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis", Proc Natl Acad Sci U S A, 99, pp.1521~1526 (2002)
138. Lievre A, "Oncogenic mutations as predictive factors in colorectal cancer", Oncogene, 29, pp.3033~3043 (2010)
139. Troiani T, "Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance", Expert Opin Biol Ther, 13, pp.241~255 (2013)
140. Chen X, "Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review", PLoS One, 8, pp.e59314~ (2013)
141. Nagahara H, "Somatic mutations of epidermal growth factor receptor in colorectal carcinoma", Clin Cancer Res, 11, pp.1368~1371 (2005)
142. Magne N, "Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (“Iressa”)", Br J Cancer, 86, pp.1518~1523 (2002)
143. Irwin ME, "Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib", J Cell Physiol, 226, pp.2316~2328 (2011)
144. Matsumoto K, "N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor", Cancer Sci, 99, pp.1611~1617 (2008)
145. Wang X, "Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling", J Biol Chem, 281, pp.2572~2577 (2006)
146. Liu YC, "Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells", Proc Natl Acad Sci U S A, 108, pp.11332~11337 (2011)
147. Park JJ, "Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells", BIOCHEMICAL PHARMACOLOGY, 83(7), pp.849~857 (2012), PERGAMON-ELSEVIER SCIENCE LTD
148. Boltje TJ, "Opportunities and challenges in synthetic oligosaccharide and glycoconjugate research", Nat Chem, 1, pp.611~622 (2009)
149. Lairson LL, "Glycosyltransferases: structures, functions, and mechanisms", Annu Rev Biochem, 77, pp.521~555 (2008)
150. Breton C, "Structures and mechanisms of glycosyltransferases", Glycobiology, 16, pp.29~37R (2006)
151. Wellen KE, "A two-way street: reciprocal regulation of metabolism and signalling", Nat Rev Mol Cell Biol, 13, pp.270~276 (2012)
152. Koike T, "Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates", Proc Natl Acad Sci U S A, 101, pp.8132~8137 (2004)
153. Horsman MR, "Imaging hypoxia to improve radiotherapy outcome", Nat Rev Clin Oncol, 9, pp.674~687 (2012)
154. Visvader JE, "Cancer stem cells in solid tumours: accumulating evidence and unresolved questions", Nat Rev Cancer, 8, pp.755~768 (2008)
155. Hittelman WN, "Are cancer stem cells radioresistant", Future Oncol, 6, pp.1563~1576 (2010)
156. Koch U, "Cancer stem cells at the crossroads of current cancer therapy failures: radiation oncology perspective", Semin Cancer Biol, 20, pp.116~124 (2010)
157. Box C, "Tumour-microenvironmental interactions: paths to progression and targets for treatment", Semin Cancer Biol, 20, pp.128~138 (2010)
158. Wang X, "Recent development in the design of sialyltransferase inhibitors", Med Res Rev, 23, pp.32~47 (2003)
159. Drinnan NB, "Inhibitors of sialyltransferases: potential roles in tumor growth and metastasis", Mini Rev Med Chem, 3, pp.501~517 (2003)
160. Chiang CH, "A novel sialyltransferase inhibitor AL10 suppresses invasion and metastasis of lung cancer cells by inhibiting integrin-mediated signaling", J Cell Physiol, 223, pp.492~499 (2010)
161. Hsu CC, "Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids", Gynecol Oncol, 96, pp.415~422 (2005)
162. Rillahan CD, "High-throughput screening for inhibitors of sialyl- and fucosyltransferases", Angew Chem Int Ed Engl, 50, pp.12534~12537 (2011)
163. Yamamoto H, "Alpha2,6-sialylation of cell-surface N-glycans inhibits glioma formation in vivo", Cancer Res, 61, pp.6822~6829 (2001)
164. Yamamoto H, "alpha2,6-Sialyltransferase gene transfection into a human glioma cell line (U373 MG) results in decreased invasivity", J Neurochem, 68, pp.2566~2576 (1997)
165. Fuster MM, "The sweet and sour of cancer: glycans as novel therapeutic targets", Nat Rev Cancer, 5, pp.526~542 (2005)

관련 논문AI추천